logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Hemophilia A

    FiltersReset Filters
    13 results

    • alhemo

      (concizumab)
      Novo Nordisk
      Usage: Alhemo is indicated for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients aged 12 and older with hemophilia A (factor VIII deficiency with inhibitors) and hemophilia B (factor IX deficiency with inhibitors).

    • altuviiio

      (Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl)
      Bioverativ Therapeutics Inc.
      Usage: ALTUVIIIO is indicated for adults and children with hemophilia A for routine prophylaxis to reduce bleeding episodes, on-demand treatment, and perioperative bleeding management. It is not intended for treating von Willebrand disease.

    • desmopressin acetate

      (Desmopressin Acetate)
      Gland Pharma Limited
      Usage: Desmopressin acetate injection is indicated for managing central diabetes insipidus, temporary polyuria and polydipsia after head trauma, and for hemophilia A and mild to moderate von Willebrand’s disease Type I to maintain hemostasis and reduce bleeding during surgeries and injuries.

    • desmopressin acetate

      (Desmopressin acetate)
      Meitheal Pharmaceuticals Inc.
      Usage: Desmopressin Acetate Injection is indicated for managing central diabetes insipidus, temporary polyuria and polydipsia post-head trauma or surgery, hemophilia A, and mild to moderate von Willebrand's disease (Type I). It helps maintain hemostasis and reduce bleeding during surgeries and after injuries. Not effective for nephrogenic diabetes insipidus.

    • hympavzi

      (marstacimab-hncq)
      Pfizer Laboratories Div Pfizer Inc
      Usage: HYMPAVZI is used for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients aged 12 and older with hemophilia A (factor VIII deficiency) or hemophilia B (factor IX deficiency), both without inhibitors.

    • sevenfact

      (Coagulation Factor VIIa Recombinant Human)
      Laboratoire Français du Fractionnement et des Biotechnologies Société Anonyme (LFB S.A.)
      Usage: SEVENFACT is indicated for treating and controlling bleeding episodes in adults and adolescents (12 years and older) with hemophilia A or B with inhibitors. It is not indicated for patients with congenital Factor VII deficiency.

    • tranexamic acid

      (Tranexamic acid)
      NorthStar RxLLC
      Usage: Tranexamic acid injection is indicated for short-term use in patients with hemophilia to reduce or prevent hemorrhage and decrease the need for replacement therapy during and after tooth extraction, typically lasting 2 to 8 days.

    • tranexamic acid

      (Tranexamic Acid)
      Heritage Pharmaceuticals Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc.
      Usage: Tranexamic acid injection, USP is indicated for short-term use in patients with hemophilia to reduce or prevent hemorrhage and decrease the need for replacement therapy during and after tooth extraction.

    • tranexamic acid

      (Tranexamic Acid)
      Emcure Pharmaceuticals Limited
      Usage: Tranexamic acid injection is indicated for short-term use (2 to 8 days) in patients with hemophilia to reduce or prevent hemorrhage and decrease the need for replacement therapy during and after tooth extraction.

    • tranexamic acid

      (Tranexamic Acid)
      Sagent Pharmaceuticals
      Usage: Tranexamic Acid in Sodium Chloride Injection is indicated for short-term use (2-8 days) in patients with hemophilia to reduce or prevent hemorrhage and decrease the need for replacement therapy during and after tooth extraction.